Rating Change
Morgan Stanley reiterated its Overweight rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) on October 27, 2026.
reiterateNASDAQ:KYMR
Morgan Stanley Reiterates Overweight Rating on Kymera Therapeutics, Inc. (KYMR)
Morgan Stanley reiterated its Overweight rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) on October 27, 2026.
At publication ·
What changed
Kymera Therapeutics, Inc. (NASDAQ:KYMR) · reiterate
- Firm
- Morgan Stanley
- Rating
- Overweight to Overweight
- Price at event
- $119.12
- Market capitalization
- $6.3B
At a glance
Key takeaways
- Morgan Stanley reiterated an Overweight rating on Kymera Therapeutics (KYMR) on October 27, 2026, with the stock trading at $119.12 and a market cap of $6.3 billion.
Market Context
Kymera Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $119.12 with a market capitalization of $6.3B.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kymera Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Kymera Therapeutics, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 27, 2026 | Morgan Stanley | Overweight | N/A |
| Oct 09, 2026 | Raymond James | Outperform | N/A |
| Oct 05, 2026 | Citigroup | Buy | N/A |
| Sep 22, 2026 | Stifel | Buy | N/A |
| Sep 14, 2026 | B of A Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KYMR Stock Page
Frequently Asked Questions
What does the Overweight rating mean for KYMR?
A rating of Overweight from Morgan Stanley reflects the analyst's outlook on Kymera Therapeutics, Inc. (NASDAQ:KYMR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KYMR forecast page.